Tracks quality of life in patients with advanced prostate cancer receiving lutetium treatment
Observes routine care with lutetium vipivotide tetraxetan in advanced prostate cancer.
Plain-language title generated from the registry record
Registry title: Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Key facts
- Where
- Aachen, Augsburg, Berlin, Bielefeld, Bonn, Braunschweig, Chemnitz, Cologne, Cottbus, Dortmund, Dresden, Erfurt, Erlangen, Essen, Frankfurt (Oder), Fulda, Halle, Herford, Homburg, Jena, Konstanz, Leipzig, Ludwigshafen, Magdeburg, Mainz, Marburg, Munich, Nuremberg, Regensburg, Rostock, Stuttgart, Trier, Tübingen, Ulm, and Würzburg, GermanySee the 35 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06517719, who can take part
Where in Germany
- AachenAachen, GermanyTaking people
- AugsburgAugsburg, GermanyTaking people
- BerlinBerlin, GermanyTaking people
- BielefeldBielefeld, GermanyTaking people
- BonnBonn, GermanyTaking people
- BraunschweigBraunschweig, GermanyTaking people
- ChemnitzChemnitz, GermanyTaking people
- CologneCologne, GermanyTaking people
- CottbusCottbus, GermanyTaking people
- DortmundDortmund, GermanyTaking people
- DresdenDresden, GermanyTaking people
- ErfurtErfurt, GermanyTaking people
- ErlangenErlangen, GermanyTaking people
- EssenEssen, GermanyTaking people
- Frankfurt (Oder)Frankfurt (Oder), GermanyTaking people
- FuldaFulda, GermanyTaking people
- HalleHalle, GermanyTaking people
- HerfordHerford, GermanyTaking people
- HomburgHomburg, GermanyTaking people
- JenaJena, GermanyTaking people
- KonstanzKonstanz, GermanyTaking people
- LeipzigLeipzig, GermanyTaking people
- LudwigshafenLudwigshafen, GermanyTaking people
- MagdeburgMagdeburg, GermanyTaking people
- MainzMainz, GermanyTaking people
- MarburgMarburg, GermanyTaking people
- MunichMunich, GermanyTaking people
- NurembergNuremberg, GermanyTaking people
- RegensburgRegensburg, GermanyTaking people
- RostockRostock, GermanyTaking people
- StuttgartStuttgart, GermanyTaking people
- TrierTrier, GermanyTaking people
- TübingenTübingen, GermanyTaking people
- UlmUlm, GermanyTaking people
- WürzburgWürzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06517719
- Record updated
- 13 July 2026
- Original description
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.Read full original descriptionShow less
Real-world Experience With Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, Multicenter, Prospective Cohort Study
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
Inclusion: All patients must meet the following inclusion criteria during the identification period:; Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1; ≥ 18 years old at the time of enrollment; Written informed consent must be obtained prior to any data collection; Willing to participate in Quality of Life post treatment date collection for 1 year.
Exclusion: Patients must not meet the following exclusion criterion during the identification period:; Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan.